Circulation, Vol 57, 685-691, Copyright © 1978 by American Heart Association
JL Anderson, JW Mason, RA Winkle, PJ Meffin, RE Fowles, L Peters and DC Harrison
The electrophysiologic properties of tocainide were evaluated by
electrophysiologic studies in 11 patients before, during and after a
constant intravenous infusion of the drug for 15 minutes. Peak plasma
tocainide concentrations averaged 11.0 +/- 1.7 microgram/ml (SEM), range
3.7 to 22.7. AH, HV, QRS, QTc and RR intervals were measured every 5
minutes during sinus and atrial-paced rhythms and showed small changes
which were not statistically significant for HV and QRS. Mild shortening of
RR was significant (P less than 0.05) at 15 minutes only. AH tended to
increase slightly for spontaneous (but not paced) rhythm, becoming
significant at 15 minutes only (P less than 0.05). QTc decreased slightly,
a change which was significant (P less than 0.05) for paced but not
spontaneous rhythm. A progressive rise in mean arterial pressure occurred
during infusion and persisted through 30 minutes (P less than 0.001).
Comparison of electrophysiologic studies at 0 and 30 minutes showed
decreased in mean effective refractory periods of atrium, A-V node, and
right ventricle by 17, 22, and 23 msec, respectively (P less than 0.05,
0.01, 0.01). Functional refractory period of the A-V node showed an average
decrease which was not significant. Sinus node recovery time and Wenckebach
cycle length were unchanged. The drug was well tolerated in all 11
patients. Hypotension in a twelfth patient may or may not have been drug
related. These results obtained at therapeutic plasma concentrations
suggest qualitative similarities between the conduction system effects of
tocainide and those published for lidocaine.
ARTICLES
Clinical electrophysiologic effects of tocainide
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1978 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |